Targeted therapies: SOLO2 confirms olaparib maintenance in ovarian cancer,Nature Reviews Clinical Oncology

当前位置： X-MOL 学术 › Nat. Rev. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Targeted therapies: SOLO2 confirms olaparib maintenance in ovarian cancer
Nature Reviews Clinical Oncology ( IF 81.1 ) Pub Date : 2017-08-16 , DOI: 10.1038/nrclinonc.2017.130
Lisa Hutchinson

Olaparib was the first PARP inhibitor approved for maintenance treatment following the practice-changing results of Study 19 — a randomized phase II trial of maintenance olaparib capsules versus placebo in patients with high-grade serous platinum-sensitive ovarian cancer. This trial demonstrated a significant treatment benefit in

中文翻译：